Truist Securities Reiterates Hold on Tandem Diabetes Care, Raises Price Target to $27
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price target from $24 to $27.
Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price target from $24 to $27.